
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is using its experience and expertise in manufacturing and production to rapidly develop COR1 for internal development and downstream commercialization. With key catalysts ahead, including the ongoing Phase 2a GAlette study and potential updates from Roche and Genentech, as well as advancements in its AlloSCOPE platform for scalability and stability, Lineage's innovative approach could lead to a competitive advantage in the emerging cell therapy market. Their focus on employing advanced biologic diagnostics and differentiation techniques to control purity and quality of their stem cell-based product is another positive sign for investors.
Bears say
Lineage Cell Therapeutics is experiencing positive results with its retinal pigment epithelium cell therapy (OpRegen) in its Phase 1/2a study and has a partnership with Roche and Genentech. However, the company faces risk factors such as clinical and financial risks, legal and intellectual property risks, and potential competition in the market. Additionally, its pipeline includes treatments for diseases with large unmet needs but currently available therapies may not demonstrate significant visual benefits, making the commercial success of these programs uncertain.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares